X4 PHARMACEUTICALS INC

X4 Pharmaceuticals lowered the recruitment target for the 4WARD phase III study to 126 patients after consulting with the FDA and says this retains 88% power for the infection‑rate endpoint and 93% for the ANC endpoint. Recruitment is now in the triple digits and accelerated after the switch to Parexel, and the company expects study completion and top‑line data in early 2026. X4 plans a US commercial model with 50–60 field sales representatives, is preparing a G‑CSF titration study to boost physician uptake, and considers funding through 2029 sufficient for the next steps. » More on de.investing.com